Fig. 5
From: MB based RT-qPCR increase the clinical application of cfEBV DNA for NPC in non-endemic area of China
The dynamic study of PEC among individuals who tested positive for cfEBV DNA in cohort 2. (A) The PEC of NPC patients at different time points who underwent neoadjuvant therapy for ≤ 2 cycles (N = 371). (B) PEC of NPC patients at different time points who received more than 2 cycles of neoadjuvant treatment. PEC: The proportion of patients with cfEBV DNA clearance upon treatment.
